likelihood of suicide, absenteeism, and the hospitalization rate. The reimbursable costs of Seroquel XR® would generate annual budget savings of PLN 8.6 million (2150 thousand €) if Seroquel XR® were used in 31% of quetiapine-treated patients with schizophrenia. The maximum savings resulting from the reimbursement of quetiapine prolonged release tablets (Seroquel XR®) could amount to PLN 27.6 million (6900 thousand €) per year. CONCLUSIONS: The reimbursement of Seroquel XR® to the reimbursable limit at the level of the reimbursement limit for normal tablets of quetiapine is profitable for the state budget – it will not only bring budgetary savings, but also allow patients to return to active life, which is crucial in the case of schizophrenia.

PMH18
THE ECONOMIC AND SOCIAL CONSEQUENCES OF SEROQUEL XR® (QUETIAPINE PROLONGED RELEASE TABLETS) REIMBURSEMENT IN BIPOLAR DISORDER TREATMENT FOR PATIENTS CURRENTLY TREATED WITH SEROQUEL (QUETIAPINE IMMEDIATE RELEASE TABLETS) IN POLAND: ANALYSIS OF THE IMPACT ON THE HEALTH CARE SYSTEM

Fabiana T1, Rzầnik M2, Pećarska R2
1AstraZeneca, Warsaw, Poland, 2Institute of Psychiatry and Neurology, Warsaw, Poland

OBJECTIVES: To estimate the economic consequences of replacing Seroquel (the normal tablets of quetiapine) with Seroquel XR® in the treatment of bipolar disorder in Poland. METHODS: Based on the estimated model of the economic consequences of bipolar disorder treatment, we calculated the cost of treating bipolar disorder with quetiapine in Poland. Expenditures for the purchase of medicines, hospital costs and the costs of lost productivity were highlighted. The analysis was performed from a societal perspective, taking into account the Fayer’s perspective in three-year time horizon. RESULTS: The use of Seroquel XR® will decrease hospitalization rate and length of hospitalisation, what will reduce direct costs of bipolar disorder treatment by PLN 645 thousand (161 thousand €uro). The use of Seroquel XR® will also increase the population of patients who will be satisfied with the recommended treatment, which will reduce the likelihood of suicide, absenteeism, and the disability pension. The budget savings related to indirect costs reduction are estimated at PLN 15.3 million (3825 thousand €uro). Moreover, the reimbursement of Seroquel XR® will increase the social transfers by PLN 157.6 thousand (39,4 thousand €uro) in comparison to current scenario. CONCLUSIONS: The reimbursement of Seroquel XR® with the reimbursement limit at the level of the reimbursement limit for normal tablets of quetiapine is profitable for the state budget – it will not only bring budgetary savings, but also allow patients to return to active life, which is crucial in the case of bipolar disorder.

PMH19
COST OF RELAPSE IN SCHIZOPHRENIA IN EUROPE: THE CONSTATRE STUDY

Hernmli M1, Diels J2, González B3, Jensen K4
1Janssen EMEA, Birkerød, Denmark, 2Janssen Pharmaceutica, Beerse, Belgium, 3Janssen, Madrid, Spain, 4Janssen EMEA, Birkerød, Denmark

OBJECTIVES: Schizophrenia is a debilitating chronic psychiatric illness with a considerable impact on the patient and the patient’s environment, in terms of morbidity, mortality, human suffering and societal costs. Currently, little is known of the economic impact of relapse in schizophrenia. Our objective is to estimate the cost of relapse based on resource utilization data collected alongside a clinical trial. METHODS: “Constatre” was a multicenter, open-label, randomized, active-control, long-term study comparing risperidone long acting injectable treatment with oral quetiapine prolonged release tablets. Patients were enrolled from October 2004 to November 2007 at 128 sites in 25 countries (ClinicalTrials.gov identifier: NCT00216476). Information regarding Medical Resource Utilization (MRU) during the three months following relapse was collected for a subset of patients. To estimate the associated relapse related costs, average overall health care costs for patients discharged stungly adjusted to the study site were used. Costs related to relapse were applied. RESULTS: Detailed MRU data were available for 63 patients spread across Europe. The overall mean MRU cost per patient in the three months following the relapse was €7592, of which 79% was related to psychiatric hospitalisation. 68% of the relapsed patients were hospitalized, for on average 38.8 days, representing a total cost of €7517 (range €277 – €20,868) per hospitalised patient. 5% of the patients were in day-clinic, on average for 41.3 days, representing a cost of €5829 per patient. The majority (60%) of the relapsed patients had outpatient visits, representing a mean cost per patient of €1834, mainly to psychiatrists (57% of patients, average age 14.5 visits) and nurses (10% of patients, average age 105.9 visits). CONCLUSIONS: Costs related to relapse of schizophrenic patients are considerable, and mainly driven by psychiatric hospitalisation. Antipsychotic treatment that prevents or reduces relapse and psychiatric hospitalisation can have a major impact on the total cost of schizophrenia related costs.

PMH20
HEALTH CARE COST COMPARISONS BETWEEN ALCOHOL OR OPIOID-DEPENDENT PATIENTS WHO WERE TREATED WITH MEDICATION AND THOSE WHO WERE NOT

Baschung, U1, Li X2
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA

OBJECTIVES: To compare the differences in health care costs between alcohol or opioid-dependent patients who were treated with pharmacological (“Any Medication”) and non-pharmacological substances (“No Medication”). METHODS: A retrospective analysis was conducted using a large U.S. health plan claims database from 2005 to 2009. Continuously eligible patients with at least one claim of alcohol/oopid dependence during the identification period, and an alcohol/oopid use disorder diagnosis during the baseline period were included. Propensity score matching (PSM) was applied to compare the risk-adjusted outcomes between the “Any Medication” and “No Medication” cohorts. Baseline differences in age, gender, region, comorbidity scores, economic status, socioeconomic status, and disease control were controlled. RESULTS: During the pre-index period, for both alcohol and opioid dependent patients, those in the “Any Medication” cohort had more distinct psychiatric diagnoses, and were more likely to have Elxhauser Index Scores of higher than 3, when compared to patients from the “No Medication” cohort. In the post-index period, for opioid-dependent patients matched for opioid-dependent patients were matched from each cohort. Patients who were treated without pharmacological medication had more rehabilitation time, a higher detoxification cost burden ($1,350,000 per 1000 patients), and higher total health care costs than patients who were treated with any medication. Similarly, there were 6,658 patients from each cohort matched for opioid-dependent patients. Patients in the “No Medication” cohort incurred higher total health care costs than patients in the “Any Medication” cohort ($14,353,000 vs. $10,192,000 per 1000 patients) during the post-index period. CONCLUSIONS: The population of opioid-dependent patients who were treated without pharmacological medication had more rehabilitation time, a higher detoxification cost burden, and higher total health care costs than patients who were treated with any medication. Alternatively, there was no significant difference in health care costs between patients who were treated with any medication.

PMH21
ECONOMIC COST OF ALCOHOL AND DRUG ABUSE IN WASHINGTON STATE, USA

Wickizer TM
University of Washington, Seattle, WA USA

OBJECTIVES: Substance Abuse (SA) represents a significant public health problem that impacts tens of millions of persons in the US and imposes over $400 billion in annual economic costs on a national basis in the form of lost productivity, premature death, criminal activity and use of medical care. The objective of this study was to estimate the economic costs associated with drug and alcohol abuse for Washington State in 2005. METHODS: We used standard cost of illness (COI) methods, relying on the prevalence approach, to estimate the costs of SA in six areas, including mortality, morbidity, treatment costs, crime, and health care. We obtained data for the analysis from various sources, including the Washington State Health Department, the National Survey on Drug Use and Health, the State Department of Corrections, and the Washington Association of County Sheriffs, and the Washington State Department of Transportation. RESULTS: We estimated costs of SA for Washington State at $5.21 billion, $832 per non-institutionalized person in the state. Alcohol abuse accounted for 56% of total costs. The per-capita, inflation-adjusted costs increased by 47% from 1996. Categories accounting for the greatest costs were mortality ($2.03 billion), crime ($1.09 billion), morbidity ($0.83 billion) and health care ($791.2 million). There were 3,324 deaths (7% of all deaths), 89,000 years of productive life lost, and 29,000 hospital discharges in 2005 in Washington associated with SA. CONCLUSIONS: SA imposes significant costs on society. Its economic costs far outweigh the resources expanded to treat persons with SA. For every $1 dollar the state collected in tax revenue for treatment from alcohol sales in 2005, $20 in economic loss was incurred from alcohol abuse. Renewed attention needs to be directed at finding more effective ways to reduce the economic and human loss arising from SA.

PMH22
ECONOMIC BURDEN OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS IN EUROPE

Nero Health Private Ltd, Chandigarh, Chandigarh, India

OBJECTIVES: This comprehensive review was conducted to report existing evidence on the economic impact of Attention Deficit Hyperactivity disorder (ADHD) in children and adolescents in Europe. METHODS: A systematic search of electronic literature databases (EMBASE and MEDLINE), was conducted from January 2001 to June 2011 to identify economic studies on ADHD in children and adolescents in Europe. All economic studies in English language, regardless of design and intervention were included. Eligibility of trials was assessed by two reviewers with any discrepancy reconciled by a third, independent reviewer. RESULTS: A total of 591 citations were retrieved out of which eight met pre-defined inclusion criteria. Five studies were cost-analyses while three were cost-effectiveness analyses. In Germany, the total direct costs for ADHD were €158 million in 2002 which increased to €287 million in 2006 with inpatient treatment costs comprising approximately 40% of the total direct costs in 2006 (Wenheiser 2002). However, inpatient costs included hospitalisations, special health-care services, comorbidities, and physician visits (Rüder 2006). The total projected costs of ADHD in Germany during 2012 are estimated to be €311 million (Schlinder 2017). The mean annual direct medical costs of ADHD patients with psychiatric comorbidities were €9580 compared to €7947 for ADHD alone in The Netherlands (Jonken 2007). The cost-effectiveness studies reviewed primarily focused on atomoxetine (ATX) and methylphenidate (MPH). ATX was found to be more cost-effective than MPH in the UK (ICER of £15 224 per QALY gained) (Cottrell 2008) as well as in Spain (ICER of €34 308 per QALY gained) (Hong 2009). CONCLUSIONS: The burden of ADHD is associated with substantial costs in Europe. Since 2002, a trend of increase in direct costs has been observed which may be due to increasing demand for healthcare services, and presence of comorbidities.

PMH23
THE ECONOMIC BURDEN OF MENTAL ILL HEALTH IN THE WORKPLACE: A COSTING APPROACH FOR BRAZILIAN EMPLOYERS

Reis TC, Takemoto MM, Takemoto ML, Fernandes RA, Tolentini ACM, Cukier FN, Santos FML, Cruz RB, Ribeiro ACP, Fernandes RRA, Moretti AJP

Reis TC, Takemoto MM, Takemoto ML, Fernandes RA, Tolentini ACM, Cukier FN, Santos FML, Cruz RB, Ribeiro ACP, Fernandes RRA, Moretti AJP
ANGOA - Knowledge Translation, Rio de Janeiro, Brazil

OBJECTIVES: There has been a growing concern about the economic burden of mental illness in Brazil. This study aims to estimate the total cost of mental illness in Brazil from a societal perspective.

METHODS: The study used thephinology study approach to estimate the cost of mental illness in Brazil. The study was conducted in a representative sample of adults aged 18 years and above in Brazil. The cost of mental illness was estimated using a societal approach, which includes direct costs (medical care, lost productivity due to illness, and informal care) and indirect costs (productivity losses due to illness).

RESULTS: The total cost of mental illness in Brazil was estimated to be $139 billion in 2011, which is equivalent to 1.5% of the country's GDP. The direct costs accounted for 65% of the total cost, while indirect costs accounted for 35%. The cost of mental illness for children was estimated to be $36 billion, which is equivalent to 2.8% of the country's GDP.

CONCLUSIONS: Mental illness in Brazil has a significant economic burden, with the cost of mental illness for children being particularly high. The study highlights the need for increased investment in mental health services in Brazil to reduce the economic burden of mental illness.

PMH24

ECONOMIC BURDEN OF MENTAL ILLNESSES IN PAKISTAN

Malik AS1, Khan MM2, Khan ZM1

1Agda Khan University, Karachi, Sindh, Pakistan, 2Agda Khan University, Karachi, Sindh, FR

OBJECTIVES: Mental illnesses in Pakistan are on the rise. This study aims to estimate the total economic burden of mental illness in Pakistan.

METHODS: The study used a bottom-up approach to estimate the cost of mental illness in Pakistan. The study included direct costs (medical care, informal care) and indirect costs (productivity losses due to illness).

RESULTS: The total cost of mental illness in Pakistan was estimated to be $3 billion, which is equivalent to 3.5% of the country's GDP. The direct costs accounted for 55% of the total cost, while indirect costs accounted for 45%.

CONCLUSIONS: Mental illness in Pakistan has a significant economic burden, with the cost of mental illness being particularly high. The study highlights the need for increased investment in mental health services in Pakistan to reduce the economic burden of mental illness.

PMH25

COSTS OF DELIVERING PSYCHIATRIC INPATIENT CARE TO MENTAL HEALTH PATIENTS WITH PSYCHOSIS AND CO-OCURRING SUBSTANCE USE: A UK BASED STUDY

Shabarudin FH1, Davies LM2

1University of Malaya, Kuala Lumpur, Malaysia, 2University of Manchester, Manchester, UK

OBJECTIVES: There is little data describing current practice in the clinical management of patients with psychosis and co-occurring substance use. The study aims to estimate the costs of delivering psychiatric inpatient care to patients with psychosis and co-occurring substance use.

METHODS: The study used a bottom-up approach to estimate the cost of psychiatric inpatient care. The study included direct costs (medical care, informal care) and indirect costs (productivity losses due to illness).

RESULTS: The total cost of delivering psychiatric inpatient care to patients with psychosis and co-occurring substance use was estimated to be $28 million, which is equivalent to 5% of the country's GDP.

CONCLUSIONS: Mental illness in Pakistan has a significant economic burden, with the cost of mental illness being particularly high. The study highlights the need for increased investment in mental health services in Pakistan to reduce the economic burden of mental illness.